<DOC>
	<DOC>NCT01415531</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy, safety, and tolerability of 8 weeks of therapy with nebivolol in comparison to placebo in younger patients 18 - 54 years of age with stage 1 or stage 2 essential hypertension.</brief_summary>
	<brief_title>Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years)</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Nebivolol</mesh_term>
	<criteria>Male and female outpatients, of age 18 54 years Patients diagnosed with stage 1 or stage 2 essential hypertension Normal physical examination findings and electrocardiogram (ECG) results or abnormal findings judged by the Investigator to be not clinically significant Secondary hypertension or severe hypertension History of Type 1 diabetes mellitus A medical contraindication to discontinuing a current antihypertensive therapy Clinically significant respiratory disease that prohibit use of a beta blocker</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>54 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Stage 1</keyword>
	<keyword>Stage 2</keyword>
	<keyword>Hypertension</keyword>
</DOC>